Dexmedetomidine in Current Anaesthesia Practice- A Review

SHAGUFTA NAAZ, ERUM OZAIR

ABSTRACT
Dexmedetomidine is an alpha 2 adrenergic receptor agonist, even ten times more selective than clonidine. It is a very versatile drug in anaesthesia practice, finding place in increasing number of clinical scenarios and is no more limited to intensive care unit (ICU) sedation. It is analgesic, has anaesthetic sparing effect, sympatholytic property, useful in other procedural sedation and also has cardiovascular stabilizing property. It reduces delirium and preserves respiratory function which adds benefits to its uses. The aim of this review is to make awareness of its role in present anaesthesia and discuss its limitations at the same time.

INTRODUCTION
Dexmedetomidine is a highly selective alpha2 adrenoceptor (α2-AR) agonist recently introduced to anaesthesia practice. It produces dose-dependent sedation, anxiolysis and analgesia (involving spinal and supraspinal sites) without respiratory depression [1,2]. Dexmedetomidine enhances anaesthesia produced by other anaesthetic drugs, causes perioperative sympatholysis and decreases blood pressure by stimulating central α2 and imidazoline receptors [3,4]. It is the dextrorotatory S-enantiomer of medetomidine and is chemically described as (+)-4-(2,3-dimethyle phenyl) ethyl-1 H-imidazole monohydrochloride with molecular weight as 236.7. The empirical formula is C_{16}H_{21}N_{2}O.HCl.

PHARMACODYNAMICS
Dexmedetomidine is a relatively selective α2 adrenoceptor agonist with a broad range of pharmacologic properties. Alpha2-AR agonists produce clinical effects after binding to G-Protein-coupled 2-AR, of which there are three subtypes (α2A, α2B, and α2C) with each having different physiological functions and pharmacological activities. These receptor subtypes are found ubiquitously in the central, peripheral, and autonomic nervous systems, as well as in vital organs and blood vessels [5]. Dexmedetomidine is 8 to 10 times more selective towards α2-AR than clonidine [6]. Alpha2 selectivity is observed following slow intravenous infusion of low and medium doses (10-300 mcg/kg). Both α1 and α2 activities are observed following slow intravenous infusion of high doses (>1000mcg/kg) or with rapid intravenous in animals. Sedative actions are believed to be mediated primarily by post-synaptic α2-adrenoceptors. Dexmedetomidine has a low affinity for beta adrenergic, muscarinic, dopaminergic and serotonin receptors. It binds the α2 receptors of locus ceruleus and spinal cord and causes sedation and analgesia respectively. Higher affinity to α2 receptor selectively leads to vagomimetic action on heart (bradycardia) and vasodilatation. The role as an antishivering agent and diuretic is yet to be established [7].

PHARMACOKINETICS
Following intravenous administration, dexmedetomidine shows rapid distribution phase with a distribution half life of six minutes and a terminal elimination half life (t1/2) of approximately two hours. Dexmedetomidine exhibits linear kinetics in the range between 0.2 - 0.7 micrograms (mcg)/kg/hr on i.v. infusion upto 24 h. In steady state, volume of distribution is about 1181. 94% is protein bound. Oral bioavailability is poor because of extensive first pass metabolism. However, after sublingual & intranasal administration bioavailability is high (84%), giving it a potential role in paediatric sedation and premedication [8].

It undergoes almost complete biotransformation with very little unchanged dexmedetomidine excreted in urine (95%) and faeces (4%) [9]. Biotransformation involves both direct glucuronidisation (the major pathway) as well as cytochrome P450 mediated metabolism.

In subjects with varying degree of hepatic and renal impairment, clearance is lower than in normal subjects, it may need dose reduction. The pharmacokinetic profile of dexmedetomidine is not altered by age.

ADVERSE EFFECTS
The most frequently observed adverse effects include hypotension, hypertension, bradycardia, dry mouth and nausea. Other reported adverse effects include fever, rigors, cyanosis, muscle weakness. It may lead to arrhythmias, AV Block, cardiac arrest, T-wave inversion, tachycardia, angina pectoris, pulmonary edema, bronchospasm, respiratory depression, syncope, neuropathy, paresthesia, paresis, hyperkalaemia, lactic acidosis and hyperglycaemia.

Tolerability of dexmedetomidine hydrochloride was noted in healthy subjects who achieved plasma concentrations from 1.8 upto 13 times the upper boundary of therapeutic range. The most notable effect observed in those who achieved the highest plasma concentration was AV block which resolved spontaneously within one minute.

DRUG ABUSE AND DEPENDENCE
The dependence potential of dexmedetomidine has not been studied in human beings but studies in rodents and primates have demonstrated clonidine like withdrawal syndrome upon abrupt discontinuation. These symptoms include nervousness, headache and agitation accompanied or followed by a rapid rise in BP and elevated catecholamine levels in the plasma.

Dexmedetomidine can be readily reversed with the specific antagonist Atipamezole [10].

DRUG INTERACTION
In vitro studies indicated that clinically relevant cytochrome P 450 mediated drug interactions are unlikely. Co-administration of anaesthetics, sedatives, hypnotics or opioids with dexmedetomidine hydrochloride is likely to lead to an enhancement of their effects. Hence, a reduction in dosage with these agents is required. Additionally, in situations where other vasodilators or negative chronotropic agents are used, co-administration of dexmedetomidine could have an additive pharmacodynamic effect and should be administered with caution and careful titration.
Dose IM injection (2.5 mcg/kg) has been used for premedication.

Addition of 0.5 µg/kg dexmedetomidine has been successfully used in intravenous route of administration (e.g., epidural, caudal, or spinal).

Its analgesic action. It prolongs the duration of both sensory and motor blockade induced by local anesthetics irrespective of the route of administration (e.g., epidural, caudal, or spinal). It enhances both central and peripheral neural blockade by local anaesthetics [26] and has been successfully used in intravenous regional anesthesia (IVRA). Addition of 0.5 µg/kg dexmedetomidine to lidocaine for IVRA improves quality of anesthesia and improves intraoperative-postoperative analgesia without causing side effects [27].

The peripheral neural blockade is due to its binding to α2A-AR [28]. Dexmedetomidine added to levobupivacaine for axillary brachial plexus block shortens the onset time and prolongs the duration of the block and postoperative analgesia [28].

Intraarticular use

Intraarticular dexmedetomidine in patients undergoing arthroscopic knee surgery improves the quality and duration of postoperative analgesia [29,30].

Controlled hypotension.

Dexmedetomidine is an effective and safe agent for controlled hypotension mediated by its central and peripheral sympathetic action. Its easy administration, predictability with anaesthetic agents, and lack of toxic side effect while maintaining adequate perfusion of the vital organs makes it a near-ideal hypotensive agent [31].

Attenuation of response to tracheal intubation and extubation

Dexmedetomidine attenuates hemodynamic stress response to intubation and extubation by its sympatholytic property [32-35]. As respiratory depression is absent, it can be continued at extubation period unlike other drugs. Dexmedetomidine, at IV doses of 0.33 to 0.67 µg/kg given 15 min before surgery attenuates the hemodynamic response to endotracheal intubation.

Anaesthetic sparing effect

When used intraoperatively in lower concentration, requirement of other anaesthetic agents is reduced. Fewer interventions are required for the treatment of tachycardia. Incidence of myocardial ischemia is also reduced. However, side effects like hypotension and bradycardia may occur, needing intervention.

Cardiovascular stabilizing effect

The cardiovascular effects of dexmedetomidine have been well studied in animal and adult human models. Growing experience, mostly in the pediatric population, has demonstrated the potential therapeutic applications of dexmedetomidine in the acute treatment of arrhythmias. Additionally, its use during cardiac surgery has been associated with a decreased incidence of postoperative ventricular and supraventricular tachyarrhythmias. Dexmedetomidine may be useful for the treatment of the deleterious cardiovascular effects of acute cocaine intoxication and overdose [36].

Cardiac surgery

Dexmedetomidine in addition to blunting the hemodynamic response to endotracheal intubation also reduces the extent of myocardial ischemia during cardiac surgery [37]. Dexmedetomidine has been successfully used to manage patients with pulmonary hypertension undergoing mitral valve replacement, with reduction in pulmonary vascular resistance, pulmonary artery pressure, and pulmonary capillary wedge pressures [38]. It is useful in off-pump Coronary Artery Bypass Grafting (CABG), vascular surgery, thoracic surgery and conventional CABG.

Neurosurgery

Besides providing cerebral hemodynamic stability, dexmedetomidine also prevents sudden increase in intracranial pressure during intubation, extubation and head pin insertion. This fact can be exploited in neuroanaesthesia. It attenuates neurocognitive impairment (delirium and agitation) allowing immediate postoperative neurological evaluation. It exerts its neuroprotective effects through several mechanisms which make the usage of this drug very promising during cerebral ischemia [39]. It does not interfere with neurological monitors [38] and has an upcoming role in “functional”

**CLINICAL APPLICATIONS**

**Premedication**

As it is a sedative, anxiolytic, analgesic, sympathetic and has stable hemodynamics, dexmedetomidine is used in premedication. It decreases oxygen consumption in intraoperative (upto8%) and postoperative period (upto 17%) [14]. The dose for premedication is 0.33– 0.67mg/kg i.v. or 2.5 µg/kg i.m. injection given 15 min before surgery.

**Intensive care unit sedation**

Dexmedetomidine is indicated for sedation in initially intubated and mechanically ventilated patients during treatment in intensive care setting. Dexmedetomidine currently is approved by FDA for use in ICU for not more than 24 hours; though many studies have reported its safe use for longer duration [15]. Dexmedetomidine has advantages for sedation in mechanically ventilated postoperative patients because it decreases requirement of opioids (>50%) and high PaO2/FIO2 with minimum respiratory depression. Dexmedetomidine is superior to midazolam and lorazepam for sedation in mechanically ventilated postoperative period (upto 17%) [14]. The dose for premedication is 0.33– 0.67mg/kg i.v. or 2.5 µg/kg i.m. injection given 15 min before surgery.

**Procedural sedation**

Dexmedetomidine is indicated for sedation of non intubated patients prior to and/or during surgical and other procedures. It has been safely used in transesophageal echocardiography [18], colonoscopy [19], awake carotid endarterectomy [20], shockwave lithotripsy [15], vitreoretinal surgery [21], paediatric patients undergoing tonsillectomy [22]. The usual dose of dexmedetomidine for procedural sedation is 1 mcg/kg, followed by an infusion of 0.2 mcg/kg/hr. Its onset of action is less than 5 min and the peak effect occurs within 15 min. Dexmedetomidine provides a titratable form of hypnotic sedation that can be easily reversed by antagonist atipamezole [10].

As an adjuvant in local & regional techniques

Highly lipophilic nature of dexmedetomidine allows rapid absorption into the cerebrospinal fluid and binding to α2-AR of spinal cord for its analgesic action. It prolongs the duration of both sensory and motor blockade induced by local anesthetics irrespective of the route of administration (e.g., epidural, caudal, or spinal). It enhances both central and peripheral neural blockade by local anaesthetics [26] and has been successfully used in intravenous regional anesthesia (IVRA). Addition of 0.5 µg/kg dexmedetomidine to lidocaine for IVRA improves quality of anesthesia and improves intraoperative-postoperative analgesia without causing side effects [27].

**Intraarticular use**

Intraarticular dexmedetomidine in patients undergoing arthroscopic knee surgery improves the quality and duration of postoperative analgesia [29,30].

Controlled hypotension.

Dexmedetomidine is an effective and safe agent for controlled hypotension mediated by its central and peripheral sympathetic action. Its easy administration, predictability with anaesthetic agents, and lack of toxic side effect while maintaining adequate perfusion of the vital organs makes it a near-ideal hypotensive agent [31].

Attenuation of response to tracheal intubation and extubation

Dexmedetomidine attenuates hemodynamic stress response to intubation and extubation by its sympatholytic property [32-35]. As respiratory depression is absent, it can be continued at extubation period unlike other drugs. Dexmedetomidine, at IV doses of 0.33 to 0.67 µg/kg given 15 min before surgery attenuates the hemodynamic response to endotracheal intubation.

Anaesthetic sparing effect

When used intraoperatively in lower concentration, requirement of other anaesthetic agents is reduced. Fewer interventions are required for the treatment of tachycardia. Incidence of myocardial ischemia is also reduced. However, side effects like hypotension and bradycardia may occur, needing intervention.

Cardiovascular stabilizing effect

The cardiovascular effects of dexmedetomidine have been well studied in animal and adult human models. Growing experience, mostly in the pediatric population, has demonstrated the potential therapeutic applications of dexmedetomidine in the acute treatment of arrhythmias. Additionally, its use during cardiac surgery has been associated with a decreased incidence of postoperative ventricular and supraventricular tachyarrhythmias. Dexmedetomidine may be useful for the treatment of the deleterious cardiovascular effects of acute cocaine intoxication and overdose [36].

Cardiac surgery

Dexmedetomidine in addition to blunting the hemodynamic response to endotracheal intubation also reduces the extent of myocardial ischemia during cardiac surgery [37]. Dexmedetomidine has been successfully used to manage patients with pulmonary hypertension undergoing mitral valve replacement, with reduction in pulmonary vascular resistance, pulmonary artery pressure, and pulmonary capillary wedge pressures [38]. It is useful in off-pump Coronary Artery Bypass Grafting (CABG), vascular surgery, thoracic surgery and conventional CABG.

Neurosurgery

Besides providing cerebral hemodynamic stability, dexmedetomidine also prevents sudden increase in intracranial pressure during intubation, extubation and head pin insertion. This fact can be exploited in neuroanaesthesia. It attenuates neurocognitive impairment (delirium and agitation) allowing immediate postoperative neurological evaluation. It exerts its neuroprotective effects through several mechanisms which make the usage of this drug very promising during cerebral ischemia [39]. It does not interfere with neurological monitors [38] and has an upcoming role in “functional”

**TABLE/FIG-1:** Routes and dosages

<table>
<thead>
<tr>
<th>Route</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intravenous</td>
<td>Loading dose of 1 mcg/kg over 10-20 minutes followed by a maintenance infusion in the range of 0.2–0.7 mcg/kg/hr. The rate of infusion can be increased in increments of 0.1 mcg/kg/hr or higher.</td>
</tr>
<tr>
<td>Intramuscular</td>
<td>IM injection (2.5 mcg/kg) of dexmedetomidine has been used for premedication.</td>
</tr>
<tr>
<td>Spinal</td>
<td>0.1–0.2 mcg/kg</td>
</tr>
<tr>
<td>Epidural</td>
<td>1–2 mcg/kg</td>
</tr>
<tr>
<td>Peripheral nerve block</td>
<td>1 mcg/kg [11]</td>
</tr>
<tr>
<td>Buccal</td>
<td>1–2 mcg/kg [8,12]</td>
</tr>
<tr>
<td>Intranasal</td>
<td>1–2 mcg/kg [12,13]</td>
</tr>
</tbody>
</table>
neurosurgery. It has been used in awake craniotomy for the resection of tumours or epileptic foci in eloquent areas, and the implantation of deep brain stimulators for Parkinson’s disease [38]. It allowed for a reduction or elimination of other sedatives, and it was particularly useful in children with chronic neurologic impairments.

In Obese patients
Dexmedetomidine does not cause respiratory depression. This fact can be utilized in sedating morbidly obese patient; thereby avoiding respiratory depression caused by narcotics [40].

Dexmedetomidine is also useful as anesthetic adjuvant in Bariatric surgery and sleep apnea patients.

Use in MRI and CT scan
High dose dexmedetomidine (3mcg/kg IV load over 10 minutes with an infusion of 1 mcg/kg/hour) has been used successfully for sedation of children undergoing MRI. Using this dose, Mason et al., [41] noted bradycardia and a 20% drop in blood pressure with minimal change in respiratory parameters.

Awake Intubation
Dexmedetomidine used for securing the airway with a fiberoptic intubation [42].

Monitored Anaesthesia Care
Dexmedetomidine has been used for sedation for monitored anesthesia care in gynaecological, urological, burns patients and trauma patients.

Post operative analgesia
Dexmedetomidine also provides intense analgesia during the postoperative period. In one study, by Venn RM et al., [43], the postoperative analgesic requirements were reduced by 50% in cardiac patients and the need for rescue midazolam for sedation was diminished by 80%.

Obstetric use
There are no adequate and well controlled studies in pregnant women. It should be used only if benefits outweigh the potential risk to the foetus.

Dexomotemide has high lipophilicity and so it passes through placenta but it disappears very fast [44]. Mahdy et al., found that after intrathecal dexmedetomidine injection there were significantly longer sensory and motor block times than patients in control and fentanyl group and there were no adverse effects on mothers or babies in any group [45]. Fynefeace-Ogan et al., found no significant differences in the APGAR score, pH of umbilical venous blood, baseline fetal heart rate and minimal change of maternal blood pressure after intrathecal administration of dexmedetomidine. The maximum sensory level reached by dexmedetomidine and fentanyl were almost the same [46]. A valid index of fetal welfare has been reported in a metaanalysis study of neonatal acid-base data with its use in the Elderly

use in the Elderly
In patients more than 65 y of age, a higher incidence of bradycardia and hypotension was observed following dexmedetomidine administration. Hence a dose reduction is needed and renal function should be monitored.

Pain and Palliative Care
Dexmedetomidine may also offer a new paradigm in the pharmacologic treatment of symptoms of distress (intractable pain, agitation or delirium) at the end of life. Recently, the FDA has approved to examine the use of dexmedetomidine in treating cancer patients at the end of life who are suffering from intractable pain, agitation or delirium [54]. It has significant opioid sparing effect and is useful in intractable neuropathic pain [55].

Other uses
Cervical spine surgery and other spine surgery. Evoked potential study and Head injury. It has been used in the treatment of alcohol and drug withdrawal of narcotics, benzodiazepines, alcohol and recreational drugs. Dexmedetomidine is effective in preventing ethanol-induced neuroregeneration. It used in the management of tetanus in ICU. It may be used as an antishivering agent.

PRECAUTIONS
Continuous electrocardiogram (ECG), blood pressure and oxygen saturation monitoring are recommended during i.v. infusion of dexmedetomidine in preexisting severe bradycardia (heart block) or ventricular dysfunction (ejection fraction <30) including decompensated congestive heart failure. Hypovolemic patients need fluid supplementation because they are prone to hypotension under dexmedetomidine therapy.

Elderly and diabetics are more prone to hypotension as it decreases sympathetic nervous activity. However, dexmedetomidine may lack amnesic properties, as a small number of patients during the study were able to recall their ICU stay and found the experience very stressful [43].

Dexmedetomidine may cause reduced larycmy. Lubrication of patient’s eye should be considered to avoid corneal dryness when using dexmedetomidine.

Limiting its usefulness is the caution that the drug cannot be bolused due to concerns about peripheral α2-receptor stimulation with resulting hypotension and bradycardia, combined with its current high cost relative to generic medications such as propofol, fentanyl and midazolam which can achieve similar clinical effects.

CONCLUSION
Dexmedetomidine is a very useful addition to the family of drugs used in anaesthesia. It can be exploited in a wide range of use as discussed above at the same time requiring vigilance during its use. High cost is its limiting factor.

REFERENCES
Shagufta Naaz et al., Dexmedetomidine in Current Anaesthesia Practice-A Review


Date of Submission: Apr 12, 2014
Date of Peer Review: Jul 31, 2014
Date of Acceptance: Aug 11, 2014
Date of Publishing: Oct 20, 2014

Date of Submission: Apr 12, 2014
Date of Peer Review: Jul 31, 2014
Date of Acceptance: Aug 11, 2014
Date of Publishing: Oct 20, 2014